Explained variation under the additive hazards model
From MaRDI portal
Publication:6627868
DOI10.1002/SIM.8763zbMATH Open1546.62615MaRDI QIDQ6627868
Publication date: 29 October 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
Cites Work
- Title not available (Why is that?)
- Dynamic path analysis for event time data: large sample properties and inference
- An information-theoretic approach to surrogate-marker evaluation with failure time endpoints
- On collapsibility and confounding bias in Cox and Aalen regression models
- Dynamic path analysis -- a new approach to analyzing time-dependent covariates
- A new approach to estimate correlation coefficients in the presence of censoring and proportional hazards
- Proportional hazards regression.
- Dynamic regression models for survival data.
- Estimation of Direct Effects for Survival Data by using the Aalen Additive Hazards Model
- Time‐dependent mediators in survival analysis: Modeling direct and indirect effects with the additive hazards model
- Instrumental variable additive hazards models
- Measures of dependence for censored survival data
- Two-sample goodness-of-fit tests for additive risk models with censored observations
- Predictive capability of proportional hazards regression.
- Semiparametric analysis of the additive risk model
- A test of fit for a semiparametric additive risk model
- A study of R2 measure under the accelerated failure time models
- On estimation of the optimal treatment regime with the additive hazards model
- A. R.2type measure of dependence for proportional hazards models
- Composite Coefficient of Determination and Its Application in Ultrahigh Dimensional Variable Screening
- On doubly robust estimation of the hazard difference
- Instrumental variable estimation in semi‐parametric additive hazards models
- Survival model construction guided by fit and predictive strength
- Estimating average regression effect under non-proportional hazards
- Comparing Kaplan-Meier curves with delayed treatment effects: applications in immunotherapy trials
Related Items (1)
This page was built for publication: Explained variation under the additive hazards model
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6627868)